Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2022 ASCO ...

The European Society for Medical Oncology (ESMO) is pleased to announce the publication of the latest version of the scale that measures the clinical benefit of cancer treatments, the ESMO-MCBS ...

Welcome to The Pharma Letter ’s real-time coverage of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

Enhancing the evaluation of the clinical benefit of cancer therapies through scientifically robust and well-validated criteria ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...